- Home
- IIIV vs TRVI Comparison
IIIV vs TRVI Comparison
Compare IIIV & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- TRVI
- Stock Information
- Founded
- IIIV 2012
- TRVI 2011
- Country
- IIIV United States
- TRVI United States
- Employees
- IIIV N/A
- TRVI N/A
- Industry
- IIIV EDP Services
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- IIIV Technology
- TRVI Health Care
- Exchange
- IIIV Nasdaq
- TRVI Nasdaq
- Market Cap
- IIIV 589.9M
- TRVI 675.8M
- IPO Year
- IIIV 2018
- TRVI 2019
- Fundamental
- Price
- IIIV $26.75
- TRVI $6.19
- Analyst Decision
- IIIV Buy
- TRVI Strong Buy
- Analyst Count
- IIIV 7
- TRVI 8
- Target Price
- IIIV $29.57
- TRVI $17.56
- AVG Volume (30 Days)
- IIIV 264.5K
- TRVI 1.2M
- Earning Date
- IIIV 05-08-2025
- TRVI 05-08-2025
- Dividend Yield
- IIIV N/A
- TRVI N/A
- EPS Growth
- IIIV 4907.14
- TRVI N/A
- EPS
- IIIV 4.75
- TRVI N/A
- Revenue
- IIIV $241,651,000.00
- TRVI N/A
- Revenue This Year
- IIIV $10.25
- TRVI N/A
- Revenue Next Year
- IIIV $12.64
- TRVI N/A
- P/E Ratio
- IIIV $5.60
- TRVI N/A
- Revenue Growth
- IIIV 5.59
- TRVI N/A
- 52 Week Low
- IIIV $18.75
- TRVI $2.30
- 52 Week High
- IIIV $29.80
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- IIIV 59.73
- TRVI 45.89
- Support Level
- IIIV $24.30
- TRVI $6.14
- Resistance Level
- IIIV $27.27
- TRVI $7.17
- Average True Range (ATR)
- IIIV 1.02
- TRVI 0.46
- MACD
- IIIV 0.04
- TRVI -0.06
- Stochastic Oscillator
- IIIV 88.26
- TRVI 5.41
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.